Paris - Delayed Quote EUR

Valbiotis SA (ALVAL.PA)

Compare
1.3660 +0.0400 (+3.02%)
At close: September 12 at 5:35 PM GMT+2
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
4,733.0000
4,733.0000
785.0000
298.0000
3,092.0000
--
Cost of Revenue
2,065.0000
2,065.0000
18.0000
16.0000
4.0000
--
Gross Profit
2,668.0000
2,668.0000
767.0000
282.0000
3,088.0000
--
Operating Expense
9,846.0000
9,846.0000
12,792.0000
8,758.0000
6,458.0000
--
Operating Income
-7,178.0000
-7,178.0000
-12,025.0000
-8,476.0000
-3,370.0000
--
Net Non Operating Interest Income Expense
-188.0000
-188.0000
-288.0000
-206.0000
-421.0000
--
Pretax Income
-7,368.0000
-7,368.0000
-12,314.0000
-8,681.0000
-3,829.0000
--
Tax Provision
--
--
-2.0000
--
--
--
Net Income Common Stockholders
-7,368.0000
-7,368.0000
-12,312.0000
-8,681.0000
-3,829.0000
--
Diluted NI Available to Com Stockholders
-7,368.0000
-7,368.0000
-12,312.0000
-8,681.0000
-3,829.0000
--
Basic EPS
-0.59
-0.59
-1.21
-0.94
-0.52
--
Diluted EPS
-0.59
-0.59
-1.21
-0.94
-0.52
--
Basic Average Shares
12,461.9870
12,461.9870
10,114.7120
9,157.8400
7,452.9030
--
Diluted Average Shares
15,773.2580
12,461.9870
10,114.7120
9,157.8400
7,452.9030
--
Total Operating Income as Reported
-7,180.0000
-7,180.0000
-12,026.0000
-8,475.0000
-3,407.0000
--
Total Expenses
11,911.0000
11,911.0000
12,810.0000
8,774.0000
6,462.0000
--
Net Income from Continuing & Discontinued Operation
-7,368.0000
-7,368.0000
-12,312.0000
-8,681.0000
-3,829.0000
--
Normalized Income
-7,368.0000
-7,368.0000
-12,312.0000
-8,681.0000
-3,794.0000
--
Interest Income
--
--
1.0000
142.0000
--
12.0000
Interest Expense
221.0000
221.0000
227.0000
229.0000
421.0000
--
Net Interest Income
-188.0000
-188.0000
-288.0000
-206.0000
-421.0000
--
EBIT
-7,147.0000
-7,147.0000
-12,087.0000
-8,452.0000
-3,408.0000
--
EBITDA
-6,411.0000
-6,411.0000
-11,235.0000
-7,511.0000
-2,371.0000
--
Reconciled Cost of Revenue
2,065.0000
2,065.0000
18.0000
16.0000
4.0000
--
Reconciled Depreciation
736.0000
736.0000
852.0000
941.0000
1,037.0000
--
Net Income from Continuing Operation Net Minority Interest
-7,368.0000
-7,368.0000
-12,312.0000
-8,681.0000
-3,829.0000
--
Total Unusual Items Excluding Goodwill
--
--
--
--
-35.0000
-26.0000
Total Unusual Items
--
--
--
--
-35.0000
-26.0000
Normalized EBITDA
-6,411.0000
-6,411.0000
-11,235.0000
-7,511.0000
-2,336.0000
--
Tax Rate for Calcs
--
--
0.0000
--
--
--
12/31/2019 - 6/7/2017

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

TGNA.F Transgene SA
1.0360
-0.96%
 
ALGAE.PA FERMENTALG
0.4275
+0.83%
 
SIGHT.PA GenSight Biologics S.A.
0.3920
+3.98%
 
ALMDP.PA Medesis Pharma S.A.
0.5480
0.00%
 
IPH.PA Innate Pharma S.A.
2.1200
-2.75%
 
ALTME.PA TME Pharma N.V.
0.1388
-0.86%
 
OSE.PA OSE Immunotherapeutics SA
6.95
-3.47%
 
ALCOX.PA Nicox S.A.
0.1552
-5.71%
 
NANO.PA Nanobiotix S.A.
4.5020
-1.05%
 
ALSEN.PA Sensorion SA
0.8900
+1.14%